People

Sales and distribution leader with previous experience at Zee Entertainment Enterprises.

Entrepreneur building solar-compatible cooling products for India.

Felicia Hosey, RAC, is identified as Cleerly’s Senior Director of Regulatory Affairs in its July 2026 FDA submission. She is a regulatory consultant and Managing Director of MDDX Solutions, with experience in medical devices and diagnostics, and serves on indieMedTech’s board. Her Cleerly appointment may be a consulting engagement; a full-time employment contract is not inferred.

Quinn Cornelius is a publicly identified Gates Ventures professional. His public professional profile identifies Gates Ventures affiliation, CFA certification and an MBA from Duke University’s Fuqua School of Business. The reviewed primary source does not disclose his exact office title or any personal cash investment.

Managing partner of Breakthrough Energy Ventures and executive director of the broader Breakthrough Energy organization; formerly worked at the Bill Gates investment office. Legal SEC name Rodrigo Guidero.

Eric Heinz serves Madison Scientific as Advisor. The company describes him as founder and managing partner of Heinz Ventures. The September2025 issuer announcement also identifies Eric S. Heinz as its founder and CEO/managing partner. Eric S. Heinz is founder and managing partner of Heinz Ventures. His own biography describes medical-device engineering, commercialization, corporate development and governance roles at Medtronic, Intuitive Surgical, Smith+Nephew and Titan Medical. He holds a bioengineering degree from Illinois, engineering-management degree from Christian Brothers and MBA from Northwestern; he is a registered patent agent. Current manager biography identifies his Madison Scientific advisory role.

Alexei Mlodinow serves Madison Scientific as Advisor. The company describes him as a surgeon and serial entrepreneur.

Joseph Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Angela Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Christopher Batterman is named by Madison Scientific as a Batterman-family hydrocephalus advocate in its advisory directory. The authentic company photograph shows the family together; it is a shared family image rather than an individually identified headshot. No individual face position, medical history or professional credential is inferred.

Haven Allen serves Madison Scientific as Board Member. The September2025 issuer financing release identifies him as chief executive of mHUB Ventures. Board membership alone is not evidence of a personal investment.

Elizabeth Hagerman serves Madison Scientific as Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

John Slump serves Madison Scientific as Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Joshua Carson serves Madison Scientific as Board Member. The March2025 financing release identifies him as a venture manager at WARF Ventures. This company board appointment does not establish a personal cash investment.

David Wesner serves Madison Scientific as Chief People Officer & VP, Operations. The current issuer directory confirms this role; an expanded professional biography is not published there.

Bermans Iskandar serves Madison Scientific as Chief Medical Officer and Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Alexander van Rosendael serves on Cleerly’s Scientific Advisory Board. ESC’s 2025 contributor profile identifies his Leiden University Medical Center affiliation.

Koen Nieman serves on Cleerly’s Scientific Advisory Board and works in cardiovascular medicine and radiology at Stanford.

Maros Ferencik serves on Cleerly’s Scientific Advisory Board and researches coronary CT imaging at Oregon Health & Science University.

Ibrahim Danad serves on Cleerly’s Scientific Advisory Board. The current ESC profile identifies his Radboud University Medical Center affiliation; recent primary research identifies cardiology. The Cleerly directory’s radiology title is not adopted as a separate current appointment.

Ricardo Cury serves on Cleerly’s Scientific Advisory Board. Its directory identifies his diagnostic radiology leadership at Florida International University.

Andrew Choi serves on Cleerly’s Scientific Advisory Board and researches cardiovascular imaging at George Washington University.

Victor Y. Cheng serves on Cleerly’s Scientific Advisory Board. His institutional biography identifies cardiovascular CT leadership at Allina’s Minneapolis Heart Institute.

Founder and CEO of Muun AI, with experience building applied AI systems. The company’s financing announcement identifies her as an AI veteran holding three machine-learning patents.

Nadim Yared is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes CVRx, Medtronic Navigation. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Tom Wilder is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes VS3 Medical, Neuros Medical, Sequent Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Dennis Wahr is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Nuvaira, Lutonix, Velocimed. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Leslie Trigg is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Outset Medical, Lutonix. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Art Taylor is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Topera, & CFO, Kyphon. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Roy Tanaka is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes J&J Biosense Webster. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Pete Sommerness is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Enterra Medical, Respicardia, Boston Sci EP. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Aaron Smith is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Artelon, Amniox Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Jeroen Bax serves on Cleerly’s Scientific Advisory Board and is a cardiologist at Leiden University Medical Center specializing in cardiac imaging.

Daniele Andreini serves on Cleerly’s Scientific Advisory Board. Its directory identifies his cardiovascular imaging work at Ospedale Galeazzi–Sant’Ambrogio.

Bruce Shook is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Vesper Medical, Intact Vascular, Neuronetics. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Louis Samson serves on Cleerly’s board and is identified as Platinum Equity’s co-president, with experience directing its investment and operating activities.

Bob Paulson is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Sonex Health, VentureMed, NxThera. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Lee Cooper serves on Cleerly’s board and is identified as AssistRx’s CEO. He previously led US Radiology. This is distinct from the Delos Capital biotechnology investor.

Tripp Peake serves on Cleerly’s board and co-founded LRVHealth. His earlier experience includes Kestrel, MassVentures and Science Park Associates. Co-founder and managing partner of LRVHealth, founded in 2000. Previously a partner at Kestrel Ventures and founder and chief executive of MassVentures, investing in research and healthcare spinoffs, following leadership of Science Park Associates in New Haven.

Tim Patrick is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Cartiva, Proxima Therapeutics. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Oscar Munoz serves on Cleerly’s board. He previously led United Airlines and held senior finance and operating positions including at CSX. Current Salesforce primary-source qualification: Oscar Munoz is a Salesforce board director. He has served on Salesforce’s board since January 2022 after membership of its global advisory board. Earlier he was United Airlines CEO and held operating leadership positions at CSX.

Rich Mott is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Relievant Medsystems, Kyphon. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Michal Sofka is Cleerly’s Chief Technology Officer. His background includes AI research for portable MRI and work at Butterfly Network, Cisco and Siemens Healthineers. He earned a computer science PhD at Rensselaer Polytechnic Institute and has experience applying deep learning to cardiac CT.

Salima Merani is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Knobbe Martens. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Christine Pellizzari is Cleerly’s Chief Legal Officer. She previously served as Science 37’s chief legal and human resources officer, including through its 2021 public listing and 2024 acquisition. Her experience spans public biotechnology legal and business leadership.

Andrew Levitch is Cleerly’s Chief Financial Officer. Its company biography also identifies his financial consulting work at FLG Partners, his founding of Finategy and sixteen years at Merck. The published role does not establish that this is a full-time employee appointment.

Angela MacFarlane is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Voyant Biotherapeutics, ForSight Vision 4, ForSight Vision 5. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Amit Relia is Chief Regulatory Officer at Cleerly. He previously led quality and regulatory compliance at iRhythm, worked on robotic medical devices at Intuitive, and supported Apple Health’s ECG and wearable software regulatory programs.

Parker Cassidy is Cleerly’s Chief Operating Officer. He previously was a partner at Sands Capital and worked at Mitra Biotech, Becton Dickinson and Upstate Biotechnology. He studied mechanical engineering at Boston University and earned an MBA at UVA Darden. His former employer’s institutional investment is not recorded as a personal investment.

Matt Likens is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes GT Medical Technologies, Ulthera. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Kimberly McCombs is Chief Strategy Officer at Cleerly and was its first employee after working with James Min at Weill Cornell. Her work covers partnerships, client services and business intelligence. She studied at the University of Arkansas and earned a healthcare administration master’s degree at Ohio University.

Malik Kahook is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes SpyGlass Pharma, ClarVista Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Udo Hoffmann is Cleerly’s Chief Medical, Scientific and AI Officer, as identified in its current leadership directory. He previously led cardiovascular imaging at Massachusetts General Hospital and was a Harvard radiology professor. His research includes ROMICAT, PROMISE and REPRIEVE. He earned a medical degree at Leipzig and an MPH at Harvard.

Jim Hartman is Chief Commercial Officer of Cleerly. He previously led health-system sales at Livongo and continued at Teladoc following its acquisition of Livongo. Earlier work included cardiovascular commercial roles at Maquet/Getinge and Boston Scientific/Guidant. He earned an MBA from NYU Stern.

Kevin Hykes is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes CVRx, Bardy Diagnostics, Relievant Medsystems, Cameron Health. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

James K. Min is Cleerly’s founder and CEO. A cardiovascular imaging researcher, he previously directed the Dalio Institute at NewYork-Presbyterian and was a professor at Weill Cornell. He studied at the University of Chicago and Temple University and completed cardiovascular training at Chicago. He founded Cleerly in 2017. James Min is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Cleerly Health, Dalio Institute of Cardiovascular Imaging. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Earl Fender is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Nalu Medical, VertiFlex, J&J DePuy Spine. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Gene de Juan is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes ForSight Labs, UCSF. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Jim Bullock is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Atritech, Endocardial Solutions. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Brad Bolzon is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Versant Ventures. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments. Brad Bolzon is Versant Ventures’ current Chairman, Managing Director. Leads firm strategy and global operations; previously headed Roche business development and held Lilly research and commercial-development roles. Holds Toronto pharmacology graduate degrees.

Adam Berman is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Alleviant Medical, TVA Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Todd Berg is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Metavention, Torax Medical. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Michael Ackermann is published by Vensana Capital as Advisor (published professional affiliation). Medtech industry advisor whose source-published professional experience includes Presidio Medical, Oculeve. These outside-company titles summarize published experience and are not independently asserted current offices, Vensana employment, company directorships or personal cash investments.

Neilly Newman is published by Vensana Capital as Executive Assistant. Minneapolis executive-support professional with earlier Versant, Polycom and Electronic Arts experience. Santa Clara psychology graduate.

Kristie Fox is published by Vensana Capital as Executive Assistant. Washington-area executive-support professional with earlier NEA and Kleiner Perkins life-sciences experience. Montana communication-studies graduate.

Elise Erkens is published by Vensana Capital as Executive Assistant. Minneapolis executive-support professional with earlier TripleTree and Värde Partners experience. Minnesota–Twin Cities child-psychology graduate.

Maggie Sullivan is published by Vensana Capital as Fund Finance Manager. Fund-finance professional supporting investment operations, financial analysis and investor relations, with prior J.P. Morgan private-bank experience and Wisconsin–Madison business education.

Steve Schwen is published by Vensana Capital as Partner and Chief Financial Officer. Venture-capital finance and operations executive with earlier Aduro, Split Rock and St. Paul Venture Capital finance leadership and KPMG experience. St. Thomas accounting graduate and inactive CPA.

Thomas Tu is published by Vensana Capital as Venture Partner. Physician and Vensana Innovation CEO with earlier Inari Medical CMO experience and interventional-cardiology practice. University of Virginia undergraduate and Harvard medical education; innovation platform leadership is separate from an invented fund.

Bill Hoffman is published by Vensana Capital as Venture Partner and Advisor. Medical-device operator and venture partner, formerly Inari CEO from 2015 to 2022 and Visualase CEO during 2008–2014. Visualase developed MRI-guided laser ablation for epilepsy and brain tumors; its pre-Vensana sale does not establish a Vensana fund investment. Also listed among Vensana advisors.

Petra Gorombei is published by Vensana Capital as Investment Professional. Clinical-evidence and operations specialist with earlier ZOLL cardiac clinical research experience. Cancer-research PhD from Paris Diderot and Duke executive MBA; published observer affiliations do not imply personal investment checks.

Allison King is published by Vensana Capital as Investment Professional. Healthcare investment professional with earlier Bank of America healthcare banking and hospital EHR consulting experience. Johns Hopkins biomedical-engineering graduate with a Duke MBA.

Mike Kramer is published by Vensana Capital as Partner. Operating and finance specialist who joined Vensana in 2021 after CRG and medical-device CFO/COO roles including Endologix, TriVascular and ATS Medical. North Dakota accounting graduate and inactive CPA.

Maria Berkman is published by Vensana Capital as Partner. Physician and investor with earlier Broadview and Longview cardiovascular and stroke investments, Monitor consulting and clinical training. Earned UCLA medical and MBA degrees.

Greg Banker is published by Vensana Capital as Partner. Medical-device investor and operator with prior Vertiflex and Navigant work spanning spine, pain intervention, neurology and robotic-surgery markets. Wisconsin–Madison biology graduate.

Kirk Nielsen is published by Vensana Capital as co-founder and Managing Partner. Medical-technology investor who co-founded Vensana in 2019 after leading Versant’s medtech practice. Earlier Medtronic, Fluidigm and Bain experience, with Harvard biology and MBA education; prior career investments are not assumed new Vensana fund checks.

Director of Strategic Investments, Ligo Partners LLC

Head Technology & Services, Investment Banking, Raymond James Financial, Inc.

Managing Director, Boston Meridian Partners

Chief Strategy & Corporate Development Officer, Everfox

Founder & Principal, Cisohive

SVP, Head of Information and Data Security, GeneDx

Deputy CISO, Cummins Engine

SVP of Engineering & CISO, Dutchie

Chief Information Security Officer, Main Line Health

CISO, Abnormal

CISO, CarGurus

Vice President of Engineering, Cisco

Adjunct Lecturer in Public Policy / Security Technologist, Harvard Kennedy School

Professor, Stanford/MIT Media Lab Alex Pentland is a published Xfund faculty/advisory affiliate. The directory supplies this professional context: Alex Pentland Toshiba Professor of Media, Arts, and Sciences at MIT. This undated published affiliation is scoped to the Xfund advisory/community network; it does not establish an investment-partner appointment, cash contribution, personal check or independently verified current outside employment.

Senior Manager of Revenue Technology, Shopify

Three-time successful CEO

Founder & CEO, Coretelligent

CFO Designate, Reading; Former Investment Banker, Guggenheim Partners

Former Chief Technology Officer, Universal Filmed Entertainment Group

Co-Founder, COO, Lighty AI; Former Director of Product Strategy & Operations, Google AI

Astrid Noltemy advises Isomer Capital and sits on its investment committee. Her venture-capital career began in the 1980s and includes Cambridge Associates, Highland Capital Partners and Charles River Ventures. Her existing Glasswing Ventures adviser affiliation is preserved independently; this Isomer role does not replace it.

Chief Technology Officer, Ziff Davis

Chair & Executive Director, Boston Children’s Hospital

Fmr. Tech Curator, TED Conferences

CRO, Nebius

Chief Information Security Officer & Chief Data Officer, Rockefeller Capital Management

Brand Director in Residence, Dow Jones

President & CEO, Ninjio

Principal, Big Digital Idea Consulting

Chief Product Officer, DoiT International

Principal, Avire Finance USA

Fmr Senior Vice President – Data, AI, and Digital, Guardian Life

Chief Growth Officer, Inrupt

Founder & Partner, Avoca Partners

Fmr. CMO

Founder and CEO, The Athena Alliance

Senior Advisor, Fmr CMO, BCG, Aetna/CVS

CIO, Gilder Office for Growth LLC

Managing Director, Rockefeller Global Family Office

Chief Commercial Officer, Convera; Former Chief Operating Officer, North America, Google

Chief Information and Technology Officer, The Kraft Group & Affiliates

Fmr. President & Chief Clinical Officer, Massachusetts General Hospital

Non-Executive Director, HSBC, YouGov

Distinguished Professor of Information Technology, Babson College

Former CMO, Dunkin’ and CEO, Digitas

SVP for AI & Data Strategy, Northeastern University/Institute for Experiential AI

Chief Marketing Officer, Rocket Software

Vice President and General Manager – Americas, HPE Aruba Networking

Marketing Advisor / CMO, Data.org

Co-founder and COO, Observo AI – a SentinelOne Company

Founder and CEO, Ascendant Network

Global CTO, Intact Insurance Specialty Solutions

Global Business Leader & Board Member; Former President, Peacock & Hulu

Director, MIT Ethical AI Initiative

Vice President of AI Applications & Platforms, Salesforce

VP of Product Management, Microsoft Fabric, Microsoft

Co-Founder & President of Marketing, Klaviyo

Senior Vice President of AI Inference, Cerebras Systems

SVP of Data, AI/ML, Engineering, Stitch Fix

Vice Chair of the Board of Directors, MSC Industrial Supply Co

Chief Commercial Officer, Four Seasons

Software Engineer, AI Infrastructure, Google

Chief ML Scientist, SVP ML/AI Eng. Tubi

Engineering Lead, Google

Senior Staff Software Engineer, Google

Senior Director, AI Innovation and Agentic Automation, Responsible AI Products, Microsoft

Professor of Entrepreneurship, Harvard Business School

Inventor, the World Wide Web

SVP and Chief Data Officer, Centene Corporation

Founder and Managing Partner at Glasswing Ventures and former GSK board member. Listed in Asepha’s joint board/advisor section; her Glasswing position is an outside affiliation, not an employee title at Asepha.

John E. Runnells is published by The Vertical Group as a general partner. He joined the firm in 1992 after co-founding Paddington Partners, which invested in special situations and public healthcare companies. Earlier, he was a partner at Webster & Sheffield. He studied business at Pennsylvania State University and law at Harvard. Board affiliations in the older firm biography are not independently asserted as current.

William Woodford is Co-founder and Chief Technology Officer at Form Energy. Co-founded Form and develops low-cost electrochemical energy-storage systems. Previously led advanced R&D at 24M Technologies. Holds a materials-science doctorate from MIT and a bachelor’s degree from Penn State.

Ted Wiley is Co-founder & President at Form Energy. Co-founded Form and oversees manufacturing, supply chain, program management and safety. Previously co-founded Aquion Energy, held product leadership at MassChallenge and led McDonough Innovation. A former US Army infantry officer.

Wes Sloan is Chief Operating Officer at Form Energy. Leads company operations. Previously an executive vice president at Panasonic Energy North America overseeing its Nevada battery operation, and spent twelve years at Rolls-Royce, including in assembly and test operations.

Tobias Schmieg is Vice President, Product Engineering at Form Energy. Leads engineering for multi-day energy-storage products. Previously led product development at Gotion High-Tech and spent eight years developing electric-vehicle battery systems at BMW.

Christopher Reynolds is Vice President, Core Technology at Form Energy. Leads battery cell design, chemistry, process selection and early scale-up. Joined Form in 2020 after leading technology and operations at AFC Energy. Studied materials science and engineering at Queen Mary University of London.

Brian Lewis is Interim General Counsel at Form Energy. Leads legal and compliance work across commercial agreements, intellectual property, governance and employment. Previously an associate general counsel at Facebook and an Assistant US Attorney in Northern California.

RJ Johnson is Chief Commercial Officer at Form Energy. Leads commercial development, policy, analytics, project engineering and service operations. Previously led Tesla Energy operations and held origination leadership at NextEra Energy Resources. A former US Army officer.

Mateo Jaramillo is Co-founder and Chief Executive Officer at Form Energy. Co-founded Form Energy after leading products and programs for Tesla’s stationary energy-storage business. Previously a founding-team member and COO at Gaia Power Technologies. Studied economics at Harvard and theology at Yale.

Kristen Ilgenstein is Vice President & Corporate Controller at Form Energy. Leads accounting, financial reporting and controls. Previously advised manufacturing companies through her consulting practice, held controller and director roles at SunPower, and worked at KPMG.

Amy Higgins is Senior Vice President, People at Form Energy. Leads people strategy, hiring, rewards and employee development. Previously CHRO at Alert Innovation, with earlier leadership at Commonwealth Fusion Systems and Aquion Energy.

Navneet Govil is Chief Financial Officer at Form Energy. Leads finance, capital formation and investor relations. Previously Executive Managing Partner and CFO at SoftBank Investment Advisers. Earlier roles included CA Technologies, SunPower, Sun Microsystems, HP and Pfizer.

Marco Ferrara is Co-founder and Chief Digital Officer at Form Energy. Leads software, analytics, data, AI and IT. Previously led software and analytics at Form, energy optimization at IHI, and storage-software development at 24M Technologies. Holds doctorates from MIT and the University of L’Aquila.

Yet-Ming Chiang is Co-founder and Chief Science Officer at Form Energy. MIT materials-science professor and co-founder of Form Energy. His research addresses materials and energy storage. Previously co-founded Desktop Metal, 24M Technologies, A123 Systems and American Superconductor.

Catherine Carmichael is Vice President, Global Supply Chain at Form Energy. Leads supply-chain strategy, procurement, supplier development and logistics. Previously led supply-chain management for Tesla energy storage and solar, and worked at PowerAdvocate and Woods Hole Oceanographic Institution.

Sarah Bray is Vice President, Communications & Corporate Affairs at Form Energy. Leads corporate communications and policy work. Previously founded clean-energy communications firm Innovant Public Relations and led public affairs at Clean Line Energy.

Mariel Bolhouse is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; historical venture fellowship rather than current employee status.

Rosemary Shults is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; historical venture fellowship rather than current employee status.

Elisabet Rosas Canyelles is listed by Santé Ventures as Fellow (Alumna). Public team directory places her in Fellow Alumni; Stanford Impact1 program and bioengineering research experience.

Yelena Wetherill is listed by Santé Ventures as Venture Fellow / Entrepreneur-in-Residence (Alumna). Public team directory places her in Fellow Alumni; biotechnology alliance and clinical development experience at Novartis.

Brandon Felkins is listed by Santé Ventures as Venture Fellow (Alumnus). Public team directory places him in Fellow Alumni; former Tangible co-founder and Stanford Biodesign educator.

Stephane Peluso is listed by Santé Ventures as Venture Fellow / Entrepreneur-in-Residence (Alumnus). Public team directory places him in Fellow Alumni; historical venture incubation followed oncology leadership at Infinity and Ipsen.

Laura McMillian is listed by Santé Ventures as Office Manager. Joined 2022; leads office administration after roles at Woodbine Capital, Centre Lane, General Atlantic and Lime Rock Partners.

Shannon Czimskey is listed by Santé Ventures as Senior Financial Accountant. Joined 2021 to oversee daily accounting operations and support portfolio companies; previously Academic Programs International.

Chas Juliano is listed by Santé Ventures as Controller. Joined 2023; oversees accounting and financial reporting after AtScale and Accomplice/Atlas Ventures finance roles.

Kyle Schroeder is listed by Santé Ventures as Senior Analyst. Joined 2025 after infrastructure finance at Starwood Property Trust and investment banking at Wells Fargo.

Ian Rahwan is listed by Santé Ventures as AI Engineer. Joined 2026 after H-E-B Digital machine learning platform engineering; UT Austin neuroscience graduate with healthcare explainable-AI research.

Ryan Hall is listed by Santé Ventures as Associate. Joined 2022 after Carlyle deal execution and portfolio management; William & Mary finance graduate.

Jake Rogers is listed by Santé Ventures as Head of Operations. Joined 2016; oversees operations after working on Santé Capital trade execution, reporting and portfolio monitoring.

Charlene Tang is listed by Santé Ventures as Venture Fellow. Healthtech operator, Stanford Biodesign fellow and former Cyted commercial lead; co-founded AptaBridge Therapeutics.

Allie Knauer is listed by Santé Ventures as Venture Fellow. Medical technology engineer and Stanford Biodesign educator, previously SparkMed business development leader.

Brendan Boland is listed by Santé Ventures as Venture Fellow & Entrepreneur-in-Residence. Combined Santé/Oxford Science Enterprises fellowship; physician co-founder of Loci Orthopaedics with medical technology operating experience.

Alana Horowitz is listed by Santé Ventures as Senior Associate. Joined 2025 after McKinsey life-sciences consulting; researched brain aging and rejuvenation at UCSF.

Mateo Vargas is listed by Santé Ventures as Senior Associate. Supports venture incubation after Stanford Biodesign and surgical robotics engineering at Verb Surgical and Auris Health.

Michael Gutbrod is listed by Santé Ventures as Principal. Joined 2021 in biotechnology investing after MIT research combining deep learning and stem-cell models of brain disorders.

Auriel August is listed by Santé Ventures as Principal. Physician and biomedical engineer focused on medtech and healthcare services; trained at Stanford and Dartmouth and formerly worked at IDEO.

Hyegi Chung is listed by Santé Ventures as Director of Accel Singapore. Leads Asian healthcare venture building after Verily APAC operations and regenerative medicine entrepreneurship.

Michael Hoffman is listed by Santé Ventures as Senior Advisor. Co-founded Palamon Capital Partners and formerly led international investing at Warburg Pincus.

Diane Brouillard is listed by Santé Ventures as Head of Talent & Networks. Leads talent and recruitment initiatives after PwC executive networking and banking recruitment roles.

Brooke Jones is listed by Santé Ventures as Head of Capital Formation. Joined 2020 following capital raising leadership at Brooklands, Bank of America, Citi and Credit Suisse.

Jeff Crawford is listed by Santé Ventures as Head of Finance. Joined 2026 to lead finance and compliance following CFO roles at Gothams and NantWorks.

William Cohn is listed by Santé Ventures as Venture Partner. Cardiac surgeon and medical device inventor, BiVACOR chief medical officer and Texas Medical Center Medical Device Labs executive director.

Thomas Krummel is listed by Santé Ventures as Venture Partner. Joined 2021; Stanford emeritus surgeon and Biodesign co-director with surgical simulation and robotics experience.

Louis Bock is listed by Santé Ventures as Venture Partner. Joined 2014 in biotechnology investing after co-founding Scale Venture Partners and roles at Gilead and Genentech.

Ashley Seehusen is listed by Santé Ventures as Venture Partner. Leads Santé Accel venture studio and formerly co-founded Nasus Medical; Stanford Biodesign educator.

Omar Khalil is listed by Santé Ventures as Managing Director. Leads Boston biotechnology practice; joined 2007 and returned2020 after pharmaceutical industry leadership.

James Eadie is listed by Santé Ventures as Managing Director. Leads medical device investing; joined 2009 and previously practiced emergency medicine with the US Air Force.

Douglas French is listed by Santé Ventures as Founding Managing Director. Co-founder and former Ascension Health chief executive and Ascension Ventures founder.

Joe Cunningham is listed by Santé Ventures as Founding Managing Director. Physician co-founder in 2006 with prior Providence Health System and Ascension Health Ventures leadership.

Also known as JM Aujero; previously held leadership roles at GCash.

Agricultural sales leader with more than ten years of sales leadership experience.

Also named Zachary David Nice; leads strategy, commercial growth and regional expansion. Previously a regional director at DGX.

Architect advising on interior design, materials specification and sustainable residential and commercial projects.

Architect with more than 30 years of design, construction and property management experience; a Certified BERDE Professional.

Entrepreneur leading a construction sourcing and procurement business in Southeast Asia.

Operating advisor of HCAP Partners specializing in healthcare operations, integration, value creation and corporate transactions. Previously held leadership roles at Gentiva/Kindred, Haven Health Care and Mission Healthcare, the latter a former HCAP Fund IV portfolio company.

Operating advisor of HCAP Partners with healthcare and technology operations, cybersecurity, turnaround and acquisition-preparation experience. Her biography describes leadership at Chordline Health and previous chief executive roles at Casamba and Brighton Rehabilitation. Historical executive positions are not inferred current appointments.

Operating advisor of HCAP Partners focused on technology, organizational change and digital transformation. Her career includes executive, board and advisory work involving Redbox/Coinstar, MOD Pizza, TrueBlue, Tealium and TIBCO; these historical organizations are not asserted as simultaneous current employers.

Operating advisor of HCAP Partners with growth-company operations and technology experience. Previously led Enli Health and held executive roles at Intel, NEC Computer Services and eFusion. His background includes governance, corporate transactions, risk management and organizational development.

Operating advisor of HCAP Partners with extensive middle-market investing, transaction structuring, operational and board experience. Previously co-founded Bunker Hill Capital and held leadership roles at Kinsman Capital, Pacific Corporate Group and Charterhouse Group. Career investment statistics span prior employers and are not HCAP fund assets.

Senior director of impact of HCAP Partners since March 2022, leading its Gainful Jobs Approach, impact management, research and portfolio workplace initiatives. Previously led Pacific Community Ventures’ research and consulting practice. He studied managerial economics at UC Davis.

Senior associate of HCAP Partners, which she joined in 2023, supporting origination, underwriting, structuring and monitoring of healthcare, technology and services investments. Previously worked in corporate and real-estate credit at Morgan Stanley and underwriting and portfolio management at Santander. She holds Columbia Business School, USC and China University of Political Science and Law degrees.

Senior partner of HCAP Partners, which he joined in 2022. He originates, structures, closes and monitors investments across healthcare, logistics, manufacturing and other sectors. Previously a principal and investment committee member at CVF Capital Partners, a Tresalia Capital investment professional, entrepreneur and Santander asset-management analyst. He holds Kellogg and Tec de Monterrey degrees.

Analyst of HCAP Partners, which he joined in 2024, supporting investment due diligence and transaction execution. Previously worked in Stifel private capital advisory. He holds a finance degree from San Diego State University; capital raised during prior employment is not an HCAP fund size.

Senior partner of HCAP Partners since joining the firm in February 2013, responsible for origination, structuring, closing and portfolio monitoring. Previously worked at DBI Capital, Citigroup fixed-income private placements and the Economic Development Bank for Puerto Rico. He holds Wharton and Columbia business degrees. His current firm biography lists healthcare, cybersecurity and software portfolio board responsibilities.

Senior partner of HCAP Partners, which he joined in May 2009. He oversees investment origination, structuring, closing, monitoring, investor relations and impact initiatives. He led the manager’s 2019 CortiCare investment. His current biography lists portfolio board or observer responsibilities at Integrated Diagnostic Services, BetterNight, Apprio, Puzzle Healthcare, Chordline and Myndshft. Previously an analyst at the Reserve Bank of Zimbabwe, he holds business and finance degrees from the University of San Diego and University of Zimbabwe.

Anna Roberts is listed in ShangBay Capital’s current public directory as Analyst. Further career biography is not published on the linked directory.

Vice president of HCAP Partners, which she joined in September 2022. Her work includes origination, diligence, underwriting and investment monitoring; the firm lists an Apprio Health board observer role. Previously worked in credit analytics and regulatory capital at Morgan Stanley, asset-backed lending at Emigrant Bank and risk management at Citigroup. She holds Columbia mathematics and NYU business degrees.

Olivia Sinkula is listed in ShangBay Capital’s current public directory as Associate. Further career biography is not published on the linked directory.

Accounting and office administrator of HCAP Partners since June 2024, responsible for accounts payable and human-resources administration. Her prior accounting work includes Gurtin and PIMCO, integration work following an acquisition, reconciliation and financial reporting across multiple industries.

Executive assistant of HCAP Partners since March 2023, supporting firm administration and executive operations. Previously served for seventeen years as executive assistant to the CEO of Garden Communities.

Vice president of HCAP Partners, which he joined in 2023. He originates, structures, closes and monitors debt and equity investments across healthcare, technology, industrial and business services sectors. Previously a vice president at CVF Capital Partners, he studied finance at Cal Poly San Luis Obispo and holds the CFA charter.

John Dai is listed in ShangBay Capital’s current public directory as Associate. Further career biography is not published on the linked directory.

Managing partner of HCAP Partners, which he joined in June 2007 after commercial banking and venture investment roles at Silicon Valley Bank and Comerica. He leads firm development and debt and equity investments in growth businesses. His current firm biography lists portfolio board and observer responsibilities including Pax Health, Lone Star Analysis, Xevant, Cubex Systems, Flume Water and IND.

Chief financial officer of HCAP Partners, overseeing fund financial operations, reporting, audit, regulatory compliance, investor financial matters and lender relationships. Previously worked in public accounting at BDO in the United States and South Africa. A Stellenbosch accounting graduate, he is a South African chartered accountant and California CPA.

Cindy Costello serves ShangBay Capital as Director of Finance & Administration. Published career biography: Cindy Costello is an accountant who has supported ShangBay since its establishment and manages its finance and administration. Her manager biography also identifies Laskey Costello and experience in business taxation, accounting and financial analysis. She earned a Cleveland State MBA and Dayton accounting degree.

Robert Kamen serves ShangBay Capital as Senior Advisor. Published career biography: Robert Kamen has biotechnology investing, scientific and executive experience. His manager biography describes Third Rock and Oxford Bioscience roles, Genetics Institute, Abbott and BASF leadership, and work on Humira development. He co-founded BioAssets and studied biophysics at Amherst and biochemistry and molecular biology at Harvard.

Andy Weimin Dai serves ShangBay Capital as Senior Advisor. Published career biography: Andy Weimin Dai works in healthcare informatics, clinical-data infrastructure and analytics, including natural-language processing and machine learning. His manager biography describes leadership at Providence and earlier informatics work at Adventist Health, IBM and Dell. These outside titles are published career information rather than independently dated appointments.

Mel Dong serves ShangBay Capital as Senior Advisor. Published career biography: Mel Dong is a former FDA specialist in premarket review and inspections who advises pharmaceutical and medical-device businesses on compliance. His manager biography identifies Blue Bell Consulting and industry training work. His education includes UNC business, Michigan State doctoral and Shanghai First Medical College medical studies.

Malcolm G. Munro serves ShangBay Capital as Senior Medical Advisor. Published career biography: Malcolm Munro advises on medical-device development, clinical research, regulatory issues and commercialization. His research concerns gynecology and minimally invasive treatment, including abnormal uterine bleeding. The manager biography identifies his consulting practice, UCLA academic affiliation and work establishing the Women’s Health Research Collaborative.

Yajun Xu serves ShangBay Capital as Senior Advisor. Published career biography: Yajun Xu has drug-discovery, biotechnology and corporate-development experience. The manager biography identifies Hongsen Investment, EpimAb and advisory or board relationships at Abcuro, Zai Lab and Hotspot. Earlier work includes ShangPharma, ChemPartner, Millennium and BASF. She earned a Brandeis biochemistry doctorate and trained at Harvard.

Michael Wallace serves ShangBay Capital as Venture Partner. Published career biography: Michael Wallace is a mechanical engineer and serial medical-device founder. His startups include DeVoro Medical, TW Medical, GW Medical and CardioProlific, which were acquired by major device companies. Earlier technical leadership includes Silk Road Medical, Baxano, Boston Scientific, BarrX and Target Therapeutics. He studied at Delaware and UC Davis.

Erik T. Engelson serves ShangBay Capital as Venture Partner. Published career biography: Erik Engelson has led medical-device companies including Dragon Vascular, Lucira Health and Medina Medical. Earlier experience includes The Foundry, Fluidigm, Versant and Institutional Venture Partners, and interventional-neuroradiology development at Target Therapeutics. He studied microbiology and bioengineering at UC San Diego and executive business at Stanford.

Chaucer Shen serves ShangBay Capital as Managing Partner. Published career biography: Chaucer Shen is a physician and medical-device investor. Before ShangBay he advised Legend Star on healthcare investments. His operating experience includes Asia-Pacific leadership at Stereotaxis and commercial or business-development roles at BarrX Medical, EV3, Boston Scientific and Medtronic.

Co-founder and CTO, leading development and technical innovation of the customer communications platform. Studied computer engineering at NUST and computer science at the University of Peshawar.

Co-founder and COO, leading growth and operations. MBA graduate of the Chinese University of Hong Kong, with earlier information management and knowledge transfer work at Kodak Alaris, Xaxis and Light Reaction.

Co-founder and CEO of respond.io, previously at IBM, Google and Runtastic and former growth leader at NDN Group. Holds an MBA from the Chinese University of Hong Kong and a Reutlingen University science degree; co-chair of the Artificial Intelligence Society of Hong Kong.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Listed in PLD Space’s published committee composition table under the Technical Advisory Committee. Advisory membership is distinct from employment or a board seat.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Published member of PLD Space’s current governance roster. Board affiliation is distinct from an employee role.

Leads strategy and public affairs. Holds a political science and sociology doctorate and public policy master’s; background includes military service, government advisory, national intelligence and state-owned real-estate strategy.

Full name Rafael Castro Padró. Aerospace engineer with more than 25 years of manufacturing experience, mainly at ITP Aero. Leads launcher production teams, industrial processes and vehicle integration.

Leads general services, with experience in management, operations, technology and business development at Inditex, Etnia Barcelona, MTNG Experience and Ferrovial Servicios.

Leads people and culture strategy, with experience in employee management and organizational change across healthcare, finance and technology. Also Ethics & Compliance Committee member under his full name José Andrés Sánchez Bueno.

Aeronautical engineer and PMI-certified programme leader, with PLD Space since 2021. Oversees strategic programmes and previously managed MIURA 1. Also Technical Advisory Committee member under her full name María Jesús Alberola Puerto.

CFO since 2022, responsible for financial strategy, operations and fundraising. ESCP Executive MBA with experience in finance for technology scaleups.

Co-founded PLD Space in 2011. Industrial engineering background; leads business strategy, new opportunities and expansion.

Co-founded PLD Space with Raúl Verdú in 2011. Leads MIURA launcher and LINCE capsule technology development and acts as launch director. Studied biological sciences and aerospace engineering; also Technical Advisory Committee member under the full name Raúl Torres Berenguer.

Executive president and published governance member; also serves on the Technical Advisory and Ethics & Compliance committees under his full name Ezequiel Sánchez Cascales. ESIC marketing graduate and ESCP MBA with experience in management education and business strategy.

Vidar Wendel-Hansen is published by SSI Strategy as NDA regulatory advisory expert. Physician and PhD with clinical-development, regulatory and medical-affairs experience in neuroscience, infectious disease and immune-mediated conditions.

Thomas Lönngren is published by SSI Strategy as NDA regulatory advisory expert. Regulatory strategy advisor and former EMA Executive Director from 2001 to 2011, with earlier Swedish Medical Products Agency leadership.

Sigrid Klaar is published by SSI Strategy as NDA regulatory advisory expert. Physician, PhD and oncologist with Swedish medicines-assessment and health-technology assessment experience, including EMA oncology and national reimbursement work.

Paula Salmikangas is published by SSI Strategy as NDA regulatory advisory expert. Advanced-therapy and biopharmaceutical regulatory expert, formerly chair of the EMA Committee for Advanced Therapies; advises on CMC and clinical-development requirements.

Patrick Salmon is published by SSI Strategy as NDA regulatory advisory expert. Pharmaceutical-medicine and rare-disease regulatory specialist with European agency and Trinity College Dublin teaching experience.

Mel Walker is published by SSI Strategy as NDA regulatory advisory expert. Commercial strategy and market-access advisor with earlier Roche, GSK and Otsuka experience, co-founder of BioPharma Futures.

Marianne Scheel Fjording is published by SSI Strategy as NDA regulatory advisory expert. Bioanalysis specialist with experience in pharmacokinetic, biomarker and immunogenicity assays and ICH M10 method-validation work.

Margarida Menezes Ferreira is published by SSI Strategy as NDA regulatory advisory expert. Biological-medicines and advanced-therapy regulatory expert with earlier Infarmed and EMA committee experience, advising on quality, comparability and manufacturing requirements.

Mads Hansen is published by SSI Strategy as NDA regulatory advisory expert. Hematologist and clinical-development expert with academic, regulatory and pharmaceutical experience; founder of ZEMA Pharma Consulting.

Karl-Heinz Huemer is published by SSI Strategy as NDA regulatory advisory expert. Regulatory advisor with neuroscience, ophthalmology, pediatric and orphan-drug experience, including EMA scientific-advice and pediatric-review work.

Jan Sjöberg is published by SSI Strategy as NDA regulatory advisory expert. Hematology and internal-medicine specialist with Swedish and Icelandic regulatory-agency experience in oncology and medicines assessment.

Frits Lekkerkerker is published by SSI Strategy as NDA regulatory advisory expert. Internal-medicine specialist and regulatory medical advisor, formerly chairing the Dutch Medicines Evaluation Board and serving on EMA committees.

Chantal Van Gils is published by SSI Strategy as Vice President, Evidence & Value (NDA regulatory network). Physician-scientist and SSI evidence-and-value leader integrating clinical evidence with regulatory, health-technology assessment and payer requirements.

Björn Carlsson is published by SSI Strategy as Vice President, Regulatory Science (NDA regulatory network). Regulatory-science leader with clinical-immunology experience and earlier Swedish Medicines Agency and EMA advanced-therapy assessment roles.

Albert L. Kraus is published by SSI Strategy as NDA regulatory advisory expert. Regulatory drug-development advisor with oncology, rare-disease and immunology experience, including earlier Pfizer work and published GDS Partners leadership.

James Wooldridge is published by SSI Strategy as Independent Executive Advisory Network member. Clinical drug developer with first-in-human and later-stage trial experience, published as Immunitas Therapeutics CMO.

Sharief Taraman is published by SSI Strategy as Independent Executive Advisory Network member. Child neurologist and clinical-informatics physician, published as Cognoa CEO. Works on autism diagnostic AI and pediatric neurology; network membership is not SSI employment or a newly inferred cash investment.

Sukumar Nagendran is published by SSI Strategy as Independent Executive Advisory Network member. Gene-therapy and rare-disease physician executive with experience in Zolgensma development and published Taysha Gene Therapies R&D leadership.

Chris Morabito is published by SSI Strategy as Independent Executive Advisory Network member. Physician-scientist with pediatric critical-care experience and later pharmaceutical-development roles at Merck, Sanofi and Takeda, including neuroscience portfolio strategy.

Fred Grossman is published by SSI Strategy as Independent Executive Advisory Network member. Physician and CNS therapeutic-development executive with experience across psychiatric and neuroscience programs at large pharmaceutical companies.

Ilan Ganot is published by SSI Strategy as Independent Executive Advisory Network member. Biotechnology executive with earlier investment-banking experience, co-founder of Solid Biosciences and published Alesta Therapeutics leadership.

Greg Fiore is published by SSI Strategy as Independent Executive Advisory Network member. Physician, former McKinsey consultant and SSI co-founder whose published biography dates founding to 2011. Later founded Fiore Healthcare Advisors and co-founded Exacis Biotherapeutics; company sales are not personal investment tickets.

Dan Bloomfield is published by SSI Strategy as Independent Executive Advisory Network member. Physician and cardiovascular drug developer with earlier Columbia academic work and Merck clinical-development leadership; trained as an Oxford Rhodes Scholar.

Howard Berman is published by SSI Strategy as Independent Executive Advisory Network member. Neuropharmacology PhD and biotechnology entrepreneur associated with Coya Therapeutics and ReAlta Life Sciences. Clinical-development and external board experience are distinct from SSI employment.

Usman Azam is published by SSI Strategy as Independent Executive Advisory Network member. Cell and gene therapy executive with earlier Novartis leadership and founding Tmunity Therapeutics. Published experience includes leading Empyrean Neuroscience; historical fundraising is not an SSI fund close.

Hanne Brokopp is published by SSI Strategy as Senior Vice President. European regulatory specialist with pharmaceutical submission, pre-submission, in-licensing and lifecycle-management experience. Current SVP card takes precedence over older VP wording in biography.

Trevor Mill is published by SSI Strategy as Senior Vice President. Drug-development and regulatory executive with neuroscience, psychiatry and rare-disease experience across early research and approvals.

Victoria Oswald is published by SSI Strategy as Senior Vice President. Chemistry PhD and early-development advisor with translational research and pharmaceutical program experience.

Minna Montgomery is published by SSI Strategy as Senior Vice President. Life-sciences advisor working on clinical and regulatory strategy, R&D programs and commercialization planning.

Max Craig is published by SSI Strategy as Senior Vice President. Consulting executive supporting medical-affairs strategy, launch preparation and cross-functional pharmaceutical operations.

Jacqui Levine is published by SSI Strategy as Senior Vice President. Management consultant with experience helping life-sciences organizations navigate organizational and development transitions.

Madhav Gurijala is published by SSI Strategy as Senior Vice President. Leads SSI’s corporate-development ventures group, strategic-investment decisions and venture-fund relationships. Biotech operator with development and operations experience; unnamed strategic investment fund size and legal vehicle are undisclosed.

Leah Damesek is published by SSI Strategy as Senior Vice President. Clinical, medical and regulatory program leader with earlier Huron Consulting experience and Vanderbilt healthcare-policy education, supporting IND preparation and governance.

Kate Goldstein is published by SSI Strategy as Senior Vice President. Life-sciences organizational consultant who joined SSI in 2011 after Deloitte strategy and operations work. Leads functional-service growth and M&A initiatives.

Heather Paden is published by SSI Strategy as Senior Vice President. Healthcare and pharmaceutical operating leader with experience supporting medical and development functions.

Jen Seda is published by SSI Strategy as Senior Vice President. Medical executive with experience leading clinical and medical teams through therapeutic development.

Benit Maru is published by SSI Strategy as Senior Vice President. Physician, neuroimmunologist and health economist working on rare-disease clinical programs, gene therapies, real-world evidence and health-technology assessments.

Amit Patel is published by SSI Strategy as Senior Vice President. Pharmacist and pharmacovigilance leader, formerly President of Fiore Healthcare Advisors before SSI’s 2021 acquisition of that consultancy.

Adriana Valenciano is published by SSI Strategy as SVP Business Consulting. Named leader of SSI’s business-consulting function. The current individual popup does not publish additional personal background; no education or prior employers inferred.

Laurie Smaldone Alsup is published by SSI Strategy as SVP Regulatory Science. Physician and regulatory-science leader advising on clinical development, regulatory pathways and innovative therapeutic programs.

Delphine Moreau is published by SSI Strategy as EVP Medical Services. Medical-affairs and pharmaceutical executive with experience in Europe and the United States, supporting medical teams and clinical strategy.

Victoria Benech is published by SSI Strategy as Chief Operating Officer. Life-sciences strategy and operations advisor helping biotech organizations manage clinical-development and organizational change.

Kim Kushner is published by SSI Strategy as Chief Business Officer. Public-health trained business leader overseeing SSI growth and client relationships; published outside affiliations include Yale lecturing and American Cancer Society governance.

Adam Schwartz is published by SSI Strategy as President. Early SSI team member and life-sciences management consultant with Acquis Consulting experience. Leads organizational planning and cross-functional development operations.

Johan Strömquist is published by SSI Strategy as President & Chief Innovation Officer. Innovation executive and author on AI risk management, with life-sciences regulatory and information-technology experience. Co-founded Metalmind in 2023 and works on generative AI and digital transformation.

Doug Locke is published by SSI Strategy as CEO. Life-sciences consulting leader focused on organizational design, governance and development milestones from proof of concept through first-in-human studies.

G. Matthew Barnard is identified in Safeguard Scientifics’ historical public directory as general counsel and secretary, alongside his authentic portrait. Mark Dow was appointed secretary in January 2024; Barnard’s current employment or general-counsel status has not been verified.

Mark A. Herndon was Safeguard Scientifics’ senior vice president and CFO until December 31, 2023, according to its primary filing. The remaining people directory displays his authentic portrait but its title predates Mark Dow’s appointment.

Eric C. Salzman was Safeguard Scientifics’ CEO until December 31, 2023, when its primary filing records the end of his executive position. The firm’s remaining people directory displays his authentic portrait but its CEO title predates Mark Dow’s January 2024 appointment.

Beth S. Michelson was identified as a Safeguard Scientifics director in its March 2024 annual report. Her current own Cartesian Capital biography describes her private equity background, University of Michigan BA, Columbia MBA and MIA, and CFA designation. Current Safeguard board status beyond the dated primary disclosure remains unconfirmed.

Joseph M. Manko Jr. was identified as Safeguard Scientifics’ board chairman in its March 2024 annual report and in KORU Medical Systems’ April 2025 proxy. His background includes Horton Capital, BZ Fund Management and investment banking.

Russell D. Glass was identified as a Safeguard Scientifics director in its March 2024 annual report. It describes his RDG Capital private investment leadership. He is distinct from the technology executive of the same name. Continued board service after this disclosure has not been independently verified from a newer primary directory.

Ross D. DeMont was identified as a Safeguard Scientifics director in its March 2024 annual report, which describes his Rainin Group investment leadership, earlier Midwood Capital management and Dartmouth MBA. Continued board service after this disclosure has not been independently verified from a newer primary directory.

Mark R. Dow is Safeguard Scientifics’ CEO, CFO and secretary, appointed January 1, 2024 through its Rock Creek Advisors engagement. Safeguard’s May 2026 tax filing confirms his CFO signature. His own Rock Creek biography describes accounting, finance, operations and restructuring experience and degrees from New England College and Northern Vermont University.

Previously a Commercial Lead at Palantir Technologies. Leads EMEA go-to-market strategy, customer relationships and regional operations.

Former President of Microsoft Spain (2021–2025) and Vice President on Microsoft’s EMEA leadership team. Supports market expansion and strategic partnerships at HappyRobot.

Previously co-founder and CTO of Nucoro, acquired by Backbase.

Previously co-founder of Cobee, acquired by Pluxee.

Previously CEO and co-founder of Colvin.

Sean Duffy is listed by CIBC Innovation Banking as Managing Director, Head of UK and Europe, based in London. He joined in 2021 to open the London office after a banking and technology career.

Amy Olah is listed by CIBC Innovation Banking as Managing Director, Head of Venture Banking, based in Toronto. She leads venture-banking origination and financing structures for Canada and the US West Coast.

Tej Sahi is listed by CIBC Innovation Banking as Managing Director, Head of Fund Finance, based in New York. He joined in 2020 to establish the unit’s fund-finance group, including subscription, capital-call and management-company financing.

Andrew Kirk is listed by CIBC Innovation Banking as Managing Director, Southeast Region Lead, based in Atlanta. His financial-services career spans more than two decades; his CIBC coverage includes B2B software and venture debt.

Walt Sparks is listed by CIBC Innovation Banking as Executive Director, Head of Syndications, based in Durham. His earlier roles included credit analysis and portfolio management at Square One Bank.

Jonathan Schupack is listed by CIBC Innovation Banking as Managing Director, based in Austin. He leads technology lending for Texas and the Mountain States.

Christopher De Ayala is listed by CIBC Innovation Banking as Director, based in Austin. He joined in 2025 and originates early-stage and growth financing in Texas from Austin.

Graham Quisenberry is listed by CIBC Innovation Banking as Director, Life Sciences and Healthcare, based in Boston. He joined the healthcare and life-sciences team in 2021 and finances growth-stage healthcare businesses.

Julie Silva is listed by CIBC Innovation Banking as Executive Director, Life Sciences and Healthcare, based in Boston. She joined the healthcare and life-sciences team in 2023 and structures debt financing for the sector.

Andrew Phillips is listed by CIBC Innovation Banking as Managing Director, Head of Sponsor Finance, based in Boston. He leads sponsor finance from Boston, focusing on investor-backed technology and software companies.

George Bixby is listed by CIBC Innovation Banking as Director, based in Boston. He joined Boston’s innovation banking team in 2023 and works with technology businesses in New England.

Andrew Schwartz is listed by CIBC Innovation Banking as Managing Director & Market Lead, based in Chicago. He helped establish The PrivateBank’s technology banking group in 2015 before that bank was acquired by CIBC.

Youssef Kabbani is listed by CIBC Innovation Banking as Managing Director, based in Menlo Park. He entered CIBC when it acquired Wellington Financial in 2018 and covers West Coast clients.

Brittany Blanco is listed by CIBC Innovation Banking as Director, based in Menlo Park. She works with California technology businesses through startup, growth and public-company stages.

Sean Thompson is listed by CIBC Innovation Banking as Managing Director & Market Lead, based in San Francisco. He moved to CIBC in 2023 after more than a decade at Silicon Valley Bank.

Sarah Perkins is listed by CIBC Innovation Banking as Director, Life Sciences and Healthcare, based in San Francisco. She joined CIBC in 2023 following work on healthcare and life-sciences transactions at Hercules Capital.

Paul Gibson is listed by CIBC Innovation Banking as Managing Director, Head of US East Coast Venture Banking, based in Reston. His venture-banking career began in California in 2000 and includes private-credit and bank leadership.

Caroline Tkatschow is listed by CIBC Innovation Banking as Managing Director, based in New York. Her sponsor-finance work supports investors and portfolio companies with non-dilutive growth financing.

Diego Recinos is listed by CIBC Innovation Banking as Director, based in Reston. He joined in 2021 and originates Mid-Atlantic financing; his earlier work included Deutsche Bank investment banking.

John Flemming is listed by CIBC Innovation Banking as Managing Director, based in Seattle. He joined CIBC in 2019 after almost sixteen years at Wells Fargo.

Paul McKinlay is listed by CIBC Innovation Banking as Executive Managing Director, Head of Innovation Banking, based in Toronto. He was a founding member of CIBC’s innovation banking team and now leads the unit.

Ravi Patel is listed by CIBC Innovation Banking as Managing Director, Head of Portfolio and Credit Solutions, based in Toronto. He entered CIBC through its MBA rotation program and now leads portfolio and credit solutions.

Robert Rosen is listed by CIBC Innovation Banking as Managing Director, based in Toronto. He joined CIBC in 2018 after leading Comerica Bank Canada’s technology and life-sciences practice.

Adam Weiers is listed by CIBC Innovation Banking as Managing Director, based in Toronto. Since joining the unit in 2018, he has worked with software investors and businesses on both sides of the Canada-US border.

Ab Makalo is listed by CIBC Innovation Banking as Director, based in Toronto. He began at CIBC in 2014 and has experience in credit investment across technology and other middle-market sectors.

Eric Laflamme is listed by CIBC Innovation Banking as Managing Director, based in Montreal. His commercial-banking experience includes Canadian and international innovation businesses.

Joe Timlin is listed by CIBC Innovation Banking as Managing Director, based in Vancouver. He joined in 2018 after a technology-investing career at BDC Venture Capital and GrowthWorks Capital.

Charlotte Goggin is listed by CIBC Innovation Banking as Director, based in London. She joined in 2022 to work on venture and growth debt for European technology businesses.

Tom Dods is listed by CIBC Innovation Banking as Executive Director, based in London. He joined the London office in 2022 after working in technology and media relationship banking.

Niramay is listed by CIBC Innovation Banking as Executive Director, based in Toronto. The bank publishes him under the single name Niramay; his work covers arranging financing for innovation businesses.

Joshua Olawale is listed by CIBC Innovation Banking as Director, based in Toronto. He provides growth financing for venture- and growth-equity-backed software companies in North America and Europe.

Jason Nardari is listed by CIBC Innovation Banking as Managing Director, Portfolio Management & Strategy, based in Toronto. He arrived with Wellington Financial in 2018 and previously headed the unit’s underwriting operation.

Kurt Nichols is listed by CIBC Innovation Banking as Head of US Early Stage & Venture Credit Solutions, Innovation Banking, based in Chicago. He joined the unit in 2021 and focuses on credit for early-stage and venture-backed US companies.

Alex Grinchteine is listed by CIBC Innovation Banking as Executive Director, Portfolio Management, based in Toronto. He entered CIBC through the Wellington Financial acquisition in 2018 and works on its innovation lending portfolio.

Scientific co-founder of ReEmerge and a medical-device researcher. Holds the endowed chair in Neurotherapeutics at the University of Florida and a PhD, as published in the company’s current directory.

Scientific co-founder of ReEmerge and an Assistant Professor of Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute. Holds a PhD.

Scientific co-founder of ReEmerge and a Stanford neurosurgeon. Holds the John and Jene Blume–Robert and Ruth Halperin professorship in Stanford’s Department of Neurosurgery.

Scientific co-founder of ReEmerge and a Weill Cornell Medicine neurologist and neuroscientist. Holds the Jerold B. Katz professorship and researches restoration of cognitive function after brain injury.

Vice President of Analytics and Strategy at ReEmerge. Holds a master’s degree, as published in the company’s current management directory.

Senior Vice President of Clinical Affairs and Operations at ReEmerge. Holds a master’s degree, as published in the company’s current management directory.

Senior Vice President of Research and Development at ReEmerge. Published in the company’s current executive team directory supporting its deep-brain-stimulation technology.

Chief Executive Officer at ReEmerge, leading development of its investigational Cognitive Network Restoration Therapy for chronic cognitive impairment after traumatic brain injury.

Eva Chickering is listed by CIBC Innovation Banking as Executive Director, based in New York. She moved to CIBC in 2026 after a decade at Standard Chartered.

Sean Foy is listed by CIBC Innovation Banking as Executive Director, Credit Solutions, based in Toronto. Since entering CIBC in 2011, he has worked in commercial banking, credit risk and innovation financing.

John Blakeley is a life-sciences technology commercial executive and board adviser. PharmaForceIQ and Eir Partners announced his appointment as PharmaForceIQ Chairman in September2024 alongside Eir’s majority growth recapitalization. Eir’s original published biography names him an operating partner and board chair of Gifthealth and PharmaForceIQ, with prior commercial leadership as CALYX Chief Commercial Officer, CRF Health Chief Business Officer, Greenphire Chief Commercial Officer and ERT Executive Vice President and Chief Commercial Officer. The original Eir affiliation is qualified as historical source-published information because he is absent from the replacement current firm roster. An authentic personal portrait was not verified.

Ian Curry is listed by CIBC Innovation Banking as Managing Director & Head of Sponsor Finance Credit Solutions, based in Toronto. He joined CIBC in 2013 and worked in global markets and corporate banking before leading sponsor-finance credit work.

Initial chair of Neo-Bionica, announced in 2021 by joint-venture partner Bionics Institute. Medtech entrepreneur and co-founder/former CEO of LBTInnovations. The current Neo-Bionica directory names Emma Cleary as chair; no exact handoverday inferred.

Published Neo-Bionica white-paper coauthor and director of R&D. Biomedical engineer with experience in active implantable neurotechnology and Synchron. Not named in the current main team directory, so current employment is unconfirmed.

Former Neo-Bionica chief technology officer; his own 2026 post states he finished the role in April. Published company white paper describes two decades of Class II/III device development and leadership at Siemens Healthcare and Advanced Bionics.

Non-executive director of Neo-Bionica representing the University of Melbourne. The company identifies him as head of enterprise partnerships and innovation initiatives at the university, with biotechnology strategy and business-development experience.

Neo-Bionica non-executive director with experience leading technology businesses. Previously senior vice president at Leica Biosystems with responsibility for advanced diagnostics.

Chair of Neo-Bionica according to its current official board directory, which publishes her authentic portrait. No undisclosed professional qualifications or appointment date are inferred.

John Turner is listed by CIBC Innovation Banking as Director, based in Austin. He entered CIBC in 2022 and has worked on venture and sponsor finance across stages of company growth.

Biomedical engineer and Sim 4 Life modelling specialist at Neo-Bionica. Previously an R&D engineer with Synchron and a postdoctoral researcher at the universities of Sydney and Melbourne, with neural-interface simulation and embedded-systems experience.

Neurotechnology and medical-device consultant at Neo-Bionica. Previously senior director at Galvani Bioelectronics and a deep-brain-stimulation therapy manager at Medtronic. His published expertise covers neuromodulation and implantable-device strategy.

Quality manager at Neo-Bionica. Earlier quality work included CSL, Cochlear and Universal Biosensors, with experience in quality systems, regulated medtech and Lean Six Sigma methods.

Atin Garg is listed by CIBC Innovation Banking as Managing Director, based in New York. He leads venture banking in New York, covering founders’ and investors’ financing and treasury needs.

Project coordinator at Neo-Bionica. Her official biography describes project-management experience in public-sector, legal and social settings. The directory’s trailing apostrophe is treated as typography rather than part of the surname.

Neo-Bionica electrofabrication technician with earlier biomedical manufacturing experience in a good-manufacturing-practice environment.

Graduate engineer at Neo-Bionica, working with Class III medical-device design and verification. The company does not disclose his degree institution or an exact appointment date.

Vidur Parmar is listed by CIBC Innovation Banking as Managing Director, Life Sciences and Healthcare, based in San Francisco. His CIBC career spans commercial banking, credit risk and leveraged finance, and he now originates West Coast healthcare transactions.

Mechanical engineer at Neo-Bionica, with prior mechanical-engineering work at Hemideina and in public hospitals. No unrelated person with the same name is inferred.

Senior electronics engineer at Neo-Bionica. His earlier R&D work included Hemideina, Planet Innovation and Blackmagic. The official biography identifies an electronics doctorate.

Senior systems engineer at Neo-Bionica. Previously worked on product development at Fisher&Paykel Healthcare.

Principal consultant at Neo-Bionica. His published career includes engineering management at Seer, Hydrix and Cochlear, with expertise in product development and risk controls. The official directory supplies a generic silhouette rather than a genuine headshot.

Neo-Bionica project director with a medtech consulting background in mechatronics and software. Her company white-paper biography describes engineering and computer-science training, more than 15 years of global consultancy and work bringing six medical products to market.

Directs engineering at Neo-Bionica, with previous engineering experience at Cochlear, Saluda and Hemideina. His published background concerns development of Class III implantable medical devices.

Leads senior business development at Neo-Bionica. Previously held executive positions with Medtronic, St Jude Medical and Abbott and worked on commercial introduction of neurostimulation and other implantable-device therapies.

Finance and governance executive serving as chief financial officer and company secretary of Neo-Bionica. The company describes experience supporting commercial development in biotechnology and life sciences.

Chief executive of Neo-Bionica. His career includes leadership at Fortive, Danaher and Siemens, including Invetech and Advanced Sterilization Products. Joint-venture partner Bionics Institute reports a doctorate from Le Havre University and international medical-device operating experience.

Deep Track Capital senior controller whose current employer biography documents a previous Broadfin Capital controller role beginning in2014, before joining Consonance Capital in2020. Exact transition days are unpublished.

Deep Track Capital operating executive whose current biography documents a former Chief Financial Officer and Chief Compliance Officer role at Broadfin Capital, beginning in April2016. The historical Broadfin affiliation does not imply current employment there.

Leads Rize’s sustainable rice farming business.

Founded RegenX and served as chief executive at its 2023 funding announcement; the release also uses the shorter name Bao Nguyen.

Entrepreneur with structured credit, portfolio management and financial technology experience, including a prior OctiFi exit.

Develops biomass fuel business opportunities and commercial partnerships in Indonesia.

Leads business operations, commercial strategy and partnerships; previously led Rize’s Indonesia operations.

Leads the agricultural waste to energy business.

Robert F. Hess serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with McGill University. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Healthcare investor and founder of Broadfin Capital. Broadfin's current website identifies him as founder and portfolio manager and describes his 2020 launch of Broadfin Holdings. SEC filings identify him as managing member of the family office; his general-partner affiliation is historically documented separately.

Eric Singman serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with the University of Maryland. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Krystel Huxlin serves Luminopia as Scientific Advisor. The company associates her ophthalmology academic career with the University of Rochester. Its published directory describes the academic title Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Peter Bex serves Luminopia as Scientific Advisor. The company associates his psychology academic career with Northeastern University. Its published directory describes the academic title Chair Of Psychology; this is a publisher biography, not an independently dated institutional appointment.

Marguerite McDonald serves Luminopia as Scientific Advisor. The company associates her ophthalmology academic career with NYU Langone. Its published directory describes the academic title Director, Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

Peter J. McDonnell serves Luminopia as Scientific Advisor. The company associates his ophthalmology academic career with the Wilmer Eye Institute. Its published directory describes the academic title Director, Professor Of Ophthalmology; this is a publisher biography, not an independently dated institutional appointment.

William Dai serves Luminopia as Board Member. The company identifies him as founding managing partner of ShangBay Capital and former chief financial officer of Boston Scientific China. His current own ShangBay biography identifies prior CFO experience at ShangPharma, Nepstar, MicroPort Scientific and Boston Scientific China, earlier Ford treasury experience, and a Michigan State MBA.

Sunny Atwal serves Luminopia as VP of Engineering. Previously served as vice president of technology at Moth+Flame and senior vice president of technology at Littlstar.

Stephanie Roberts serves Luminopia as Head of Market Access. Previously served as senior director of national accounts at Akili and national accounts director at Otsuka and Acorda.

Shelley Hancock serves Luminopia as Sr Director, Medical Affairs. Previously served as senior director of medical and professional affairs at Clearside Biomedical.

Scott Xiao serves Luminopia as Co-Founder and CEO and Board Member. Co-founded Luminopia and is its chief executive officer and a board member. Its published biography lists MIT Technology Review Innovators Under 35 and Forbes 30 Under 30 recognition.

Hank Wu serves Luminopia as COO. Previously served as vice president of digital at Evelo Biosciences and director at Biogen.

Drew Mowery serves Luminopia as VP of Commercial Strategy. Previously served as senior director at Ultragenyx Pharmaceutical and director at bluebird bio and Genentech.

Bruce Kent serves Luminopia as National Sales Director. Former National Sales Director, Specialty Brands, Inside Sales & Marketing Support at Harrow. Former Vice President, Delta Point.

Brion Raymond serves Luminopia as CBO. Former CCO at Clearside Biomedical. Former Director at Genentech.

Matt Forman is Vice President, Finance at Eir Partners. Finance professional with earlier Cano Health accounting leadership and PwC experience. Holds Florida State accounting degrees and an active Florida CPA qualification.

Mike Huxsol is Chief Financial Officer & Chief Compliance Officer at Eir Partners. Oversees firm financial and compliance matters; joined in 2024 following private-equity finance experience including Baird Capital and PwC. Holds Wisconsin–Whitewater accounting degrees and an inactive Wisconsin CPA qualification. Current title includes CCO, unlike the older manager page.

Sebastian de la Torre is Associate at Eir Partners. Supports investments and portfolio initiatives with earlier Martis Capital and Bank of America investment-banking experience. Vanderbilt economics graduate.

Jake Robbins is Associate at Eir Partners. Supports healthcare investments following Welsh, Carson, Anderson & Stowe and Solomon Partners healthcare M&A work. University of Pennsylvania international-relations graduate.